U.S. label record. The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Four selected reports cover randomized trials in erythropoietic protoporphyria (EPP), an observational EPP cohort, combination treatment in vitiligo, and an exploratory stroke study. This is a selected overview, not a completed systematic review.↗↗↗↗
What the reviewed sources report
The EPP trials reported longer pain-free sunlight exposure. Evidence in vitiligo concerns combination treatment with phototherapy; the six-person stroke study cannot establish treatment benefit or safety. Results from these different settings should not be pooled.↗↗↗↗
What remains unresolved?
How durable are benefits and harms in broader EPP populations, including those underrepresented in the trials?↗↗↗↗
What do controlled studies establish in indications beyond EPP, and how do combination treatments affect attribution?↗↗↗↗
The cited implant label covers increased pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions. This is not a general tanning or cosmetic indication. Label: indications and usage ↗
Which safety limits matter?
The label contraindicates severe hypersensitivity and reports postmarketing anaphylaxis. It also describes increased pigmentation and darkening of existing skin lesions, with skin monitoring addressed in the warnings. Label: contraindications, warnings and precautions ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Label ZIP SHA-256: 2524c0069e687a8d327718fa17678071dd3c817a42624f569870344888f34e29. Extracted XML SHA-256: d58fc4df343aa1a49a633ed2fbfb46eb5cc94ec6d9e059a4e1d86d4dd1f43397.
FDA’s 2019 review supported approval for increased pain-free light exposure in adults with erythropoietic protoporphyria. In CUV039, the sponsor’s analysis gave p=0.044; FDA’s analysis including missing-data assumptions gave p=0.055. FDA considered CUV029 supportive, while CUV030’s pain-free exposure analysis was post hoc. FDA PDF pp. 19, 20, 118 ↗
More findings, study links and document coverage
Which limitations affect interpretation?
FDA described diary-design and data-handling problems, different exposure windows and follow-up periods, and uncertainty about the quality-of-life instruments. Twenty-six participants from CUV030 could re-enroll in CUV039, so the trial enrollment totals do not represent entirely distinct people. FDA PDF pp. 21, 117, 118, 119 ↗
What safety work was requested?
The 2019 review requested a cardiac-repolarization study and a long-term registry addressing skin cancer, implant reactions, pregnancy and device issues. These were surveillance questions, not proof that the medicine caused those outcomes. Their current completion status has not been verified in this review. FDA PDF pp. 144, 147, 148 ↗
Selected sections read in 1 of 16 inventoried documents; 15 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
English PDF entries containing Scenesse in the title in the retained September 15 EMA document-feed snapshot, plus selected FDA approval-package documents. Includes candidate associations, not a complete FDA inventory, national authorizations or worldwide coverage. Live EMA page requests returned HTTP 429 on September 16; fresh page reconciliation is pending. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Not yet reviewed · ema-4290 · Document/feed date: 2025-10-21
Discovered in the retained EMA document feed; product/application association and substantive content are not yet verified.
Feed-listed application (not a verified association): EMEA/H/C/002548.
Remaining work
Review the remaining EMA assessment, product-information, risk-management and change documents; reconcile historical applications separately.
Reconcile later FDA supplements and current postmarketing-study status. Earlier review conclusions are dated evidence, not a current approval-status substitute.
Complete full-text and correction appraisal of the related literature. Registry identity matching does not establish that all posted results or historical registry versions have been reviewed.
European medicine records · 1 products or applications
EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.
Active substance as listed: afamelanotide. EMA record ↗
Marketing authorisation: 2014-12-22. EMA metadata last updated 2026-01-30. EMA metadata ↗
Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.
296 retrieved · 4 included · 0 excluded · 292 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
"Afamelanotide"[Title/Abstract] OR "NDP-MSH"[Title/Abstract] OR "melanotan I"[Title/Abstract] OR "Scenesse"[Title/Abstract]
Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.
Showing 25 of 296 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 40082741 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: afamelanotide-PMID40082741-registry-linkage-unresolved.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 37496004 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT04962503.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 26132941 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT00979745; NCT01605136.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 25230094 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01430195.Bibliographic record recheck · 2026-09-15
The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗
PubMed 42678656 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42621255 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42569625 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 42394403 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41999898 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41890775 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41885813 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41854307 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41793078 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41766687 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41758331 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41718315 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41547183 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41542313 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41489668 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41466311 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41165369 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41118158 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 41002740 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 40858983 — not screened: Name-query match awaiting clinical eligibility screening.
PubMed 40817749 — not screened: Name-query match awaiting clinical eligibility screening.
FDA search
Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA210797 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: AFAMELANOTIDE.
EMA search
Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EMEA/H/C/002548 — include: EMA feed product Scenesse; reported status: Authorised. Exact indication and decision documents remain unappraised.
EMA search
Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.
19 retrieved · 8 included · 0 excluded · 11 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 19 of 19 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA 19438 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - All Authorised presentations
EMA 25189 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Public assessment report
EMA 41502 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Summary for the public
EMA 69274 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Procedural steps taken and scientific information after authorisation
EMA 38510 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Risk management plan
EMA 33409 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Procedural steps taken and scientific information after authorisation (archive)
EMA 72369 — include: Document linked by EMA product number; content unappraised. Scenesse-PAM-0000291457 : EPAR - Assessment report
EMA 4290 — include: Document linked by EMA product number; content unappraised. Scenesse : EPAR - Product Information
EMA 14965 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Scenesse
EMA 17497 — not screened: Title-name match awaiting identity and document review. Scenesse recommended for rare disease that causes intolerance to sunlight
EMA 22343 — not screened: Title-name match awaiting identity and document review. EU/3/09/648: Public summary of positive opinion for orphan designation of
afamelanotide for the treatment of solar urticaria
EMA 37594 — not screened: Title-name match awaiting identity and document review. Recommendation for maintenance of orphan designation at the time of marketing authorisation: Scenesse (afamelanotide) for the treatment of erythropoietic protoporphyria
EMA 41718 — not screened: Title-name match awaiting identity and document review. EU/3/14/1285: Public summary of opinion on orphan designation: Afamelanotide for the treatment of familial benign chronic pemphigus (Hailey-Hailey disease)
EMA 63429 — not screened: Title-name match awaiting identity and document review. Withdrawal letter: Scenesse
EMA 64302 — not screened: Title-name match awaiting identity and document review. P/0101/2024 : EMA decision of 12 April 2024 on the acceptance of a modification of an agreed paediatric investigation plan for afamelanotide (Scenesse), (EMEA-000737-PIP02-11-M03)
EMA 5096 — not screened: Title-name match awaiting identity and document review. P/292/2011: EMA decision of 2 December 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for afamelanotide (EMEA-000737-PIP02-11)
EMA 40429 — not screened: Title-name match awaiting identity and document review. P/185/2010: European Medicines Agency decision of 24 September 2010 on the granting of a product specific waiver for afamelanotide (EMEA-000737-PIP01-09)
EMA 63430 — not screened: Title-name match awaiting identity and document review. Questions and answers on the withdrawal of application to change the marketing authorisation for Scenesse (afamelanotide)
EMA 72863 — not screened: Title-name match awaiting identity and document review. Withdrawal assessment report for Scenesse
EMA search
Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.
5 retrieved · 5 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Document appraisal and national European sources remain open.
Zero matches apply only to these feed fields and terms; orphan designation is not approval.
Showing 5 of 5 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/08/541 — include: EMA orphan feed identifies [Nle4, D-Phe7]-alfa-melanocyte stimulating hormone (afamelanotide); designation status: Expired. Orphan designation is not marketing authorization.
EMA EU/3/24/2947 — include: EMA orphan feed identifies afamelanotide; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/24/2926 — include: EMA orphan feed identifies afamelanotide; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/09/648 — include: EMA orphan feed identifies afamelanotide; designation status: Positive. Orphan designation is not marketing authorization.
EMA EU/3/14/1285 — include: EMA orphan feed identifies afamelanotide; designation status: Positive. Orphan designation is not marketing authorization.
ClinicalTrials.gov search
ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.
23 retrieved · 0 included · 0 excluded · 23 awaiting a decision · 0 full-text appraisals
Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
Other registries, unregistered studies and additional aliases remain outside this query.
Showing 23 of 23 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT00829192 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04578496 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00979745 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01430195 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04704713 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06388642 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01382589 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00859534 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT00472901 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04525157 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01097044 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT06109649 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04962503 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04425746 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05210582 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT01605136 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05854784 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05370235 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05159752 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT05368857 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04053270 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT04943159 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
ClinicalTrials.gov NCT03634137 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
Read the full Human Evidence Review
Supervised synthesis
What do selected human studies report about Afamelanotide?
Four selected reports cover randomized trials in erythropoietic protoporphyria (EPP), an observational EPP cohort, combination treatment in vitiligo, and an exploratory stroke study. This is a selected overview, not a completed systematic review.1234
Bottom line from this bounded source set
The EPP trials reported longer pain-free sunlight exposure. Evidence in vitiligo concerns combination treatment with phototherapy; the six-person stroke study cannot establish treatment benefit or safety. Results from these different settings should not be pooled.1234
Reviewed study record
EPP: two placebo-controlled trials in one report
Design
Two randomized, blinded trials followed participants for six or nine months.1
Population
The European trial enrolled 74 patients with EPP and the US trial enrolled 94.1
Outcomes reported
The authors reported longer pain-free sunlight exposure and improved quality of life with afamelanotide. Adverse events were mostly mild; serious events were assessed as unrelated to treatment.1
Limitations
The report contains two trials with different follow-up periods and sunlight-exposure measurements. Their numeric exposure results should not be directly compared; limited follow-up cannot resolve uncommon long-term harms.1
Reviewed study record
EPP: German post-authorization cohort
Design
An observational registry study evaluated treated patients without an untreated comparison group.2
Population
The report describes 200 patients with EPP in the German post-authorization safety study.2
Outcomes reported
Quality-of-life scores improved relative to baseline, and 91% continued treatment at the reported cutoff. The study also collected treatment-emergent adverse events.2
Limitations
Without an untreated comparator, changes cannot establish a causal treatment effect. Treatment continuation is not proof of safety, and treatment selection can introduce bias.2
Reviewed study record
Vitiligo: afamelanotide plus phototherapy
Design
A randomized multicenter study compared afamelanotide plus narrowband UV-B with phototherapy alone.3
Population
The study enrolled 55 adults with nonsegmental vitiligo and Fitzpatrick skin phototypes III–VI.3
Outcomes reported
The combination group had greater reported repigmentation at day 168. Erythema occurred in both groups; nausea and minor infections were reported in the combination group.3
Limitations
The study does not isolate afamelanotide without phototherapy or establish results in all skin phototypes. PubMed links subsequent correspondence about the study.3
Reviewed study record
Acute stroke: early feasibility study
Design
An open-label Phase 2a study assessed safety and exploratory recovery measures without a control group.4
Population
Six patients with acute ischemic stroke who were ineligible for revascularization therapies were enrolled.4
Outcomes reported
The surviving patients showed neurological improvement. One patient died after a recurrent stroke, which investigators assessed as unrelated to the study drug.4
Limitations
Six uncontrolled observations cannot distinguish drug effects from natural recovery or establish safety. The authors called for randomized studies.4
Reviewed source set
PubMed · 26132941Afamelanotide for Erythropoietic Protoporphyria. ↗PubMed PMID 26132941 · EFetch XML reviewed 2026-09-15 · payload SHA-256 b94a37b2a147aaedfdcff20011049a0589c73cd3790c0e727e5e8a209b2d802f
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1411481. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1111/phpp.13012. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1001/jamadermatol.2014.1875. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1186/s12883-023-03338-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Afamelanotide?
U.S. label record. The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 20 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
11
Canonical profile
Published
Profile structured data
Published
Linked dated records
55
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
DailyMed lists Structured Product Labeling version 1 for the reviewed Afamelanotide label family with a published date of 2019-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 10 for the reviewed Afamelanotide label family with a published date of 2026-02-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 11 for the reviewed Afamelanotide label family with a published date of 2026-05-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.
Evidence summary
What the cited records say
The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗
This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.
PeptideScanner retained ClinicalTrials.gov record NCT06388642 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-27, and PeptideScanner's reviewed identity mapping was afamelanotide.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41547183 at 2026-07-30T16:14:14.777Z. PubMed recorded a metadata revision date of 2026-06-26 and an Entrez history date of 2026-01-17. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗
DailyMed lists Structured Product Labeling version 11 for the reviewed Afamelanotide label family with a published date of 2026-05-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41793078 at 2026-07-30T16:23:41.287Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2026-03-07. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38634774 at 2026-07-30T16:23:36.263Z. PubMed recorded a metadata revision date of 2026-03-06 and an Entrez history date of 2024-04-18. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38736212 at 2026-07-30T16:23:36.274Z. PubMed recorded a metadata revision date of 2026-03-06 and an Entrez history date of 2024-05-13. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗
DailyMed lists Structured Product Labeling version 10 for the reviewed Afamelanotide label family with a published date of 2026-02-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25494545 at 2026-07-30T16:30:52.686Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-12-16. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.↗
PubMed lists PMID 41542313 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
DailyMed lists Structured Product Labeling version 9 for the reviewed Afamelanotide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
PubMed lists PMID 40692281 in Clinical and experimental dermatology as Journal Article, with publication-date metadata of 2025-10-27 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
DailyMed lists Structured Product Labeling version 8 for the reviewed Afamelanotide label family with a published date of 2024-08-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗